Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Edetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.82 |
| ▸ | EYA2 | O00167 | 1/20 | 0.82 |
| ▸ | APP | P05067 | 1/20 | 0.82 |
| ▸ | ACE | P12821 | 1/20 | 0.82 |
| ▸ | BLM | P54132 | 2/20 | 0.78 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.78 |
| ▸ | TSHR | P16473 | 2/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.78 |
| ▸ | DRD1 | P21728 | 1/20 | 0.78 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.78 |
| ▸ | DRD3 | P35462 | 1/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.78 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL247531 | 1.00 | TDP1 (0.82) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL1363382 | 1.00 | TDP1 (0.82) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL30569658 | 1.00 | TDP1 (0.82) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL668797 | 0.97 | TDP1 (0.78) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL10632169 | 0.97 | TDP1 (0.78) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL10937476 | 0.97 | TDP1 (0.78) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL2471967 | 0.97 | TDP1 (0.78) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL11053686 | 0.97 | TDP1 (0.78) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL6418284 | 0.97 | TDP1 (0.78) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL10906870 | 0.97 | TDP1 (0.78) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119192558-A | Polyphenylene ether resin, composition, preparation method and application thereof | 万华化学集团股份有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-113827568-B | Endoplasmic reticulum membrane fusion liposome and preparation method and application thereof | 山东大学 | 2022-07-26 | — | — | CN | claimed |
| US-9777022-B2 | Process for the preparation of macrocyclic polyazacarboxylate ligands and chelates | GUERBET (FR) | 2017-10-03 | — | — | US | claimed |
| EP-2920156-B9 | PROCESS FOR THE PREPARATION OF MACROCYCLIC POLYAZACARBOXYLATE LIGANDS AND CHELATES | GUERBET SA (FR) | 2017-04-19 | — | — | EP | claimed |
| EP-2920156-B1 | PROCESS FOR THE PREPARATION OF MACROCYCLIC POLYAZACARBOXYLATE LIGANDS AND CHELATES | GUERBET SA (FR) | 2016-12-07 | — | — | EP | claimed |
| US-20160185803-A1 | PROCESS FOR THE PREPARATION OF MACROCYCLIC POLYAZACARBOXYLATE LIGANDS AND CHELATES | MALLINCKRODT LLC | 2016-06-30 | — | — | US | claimed |
| US-9315474-B2 | Process for the preparation of macrocyclic polyazacarboxylate ligands and chelates | LIEBEL-FLARSHEIM COMPANY LLC (US) | 2016-04-19 | — | — | US | claimed |
| US-20150259304-A1 | PROCESS FOR THE PREPARATION OF MACROCYCLIC POLYAZACARBOXYLATE LIGANDS AND CHELATES | GUERBET (FR) | 2015-09-17 | — | — | US | claimed |
| US-20110265834-A1 | Intravascular Line and Port Cleaning Methods, Methods of Administering an Agent Intravascularly, Methods of Obtaining/Testing Blood, and Devices for Performing Such Methods | TENNICAN PATRICK O | 2011-11-03 | — | — | US | claimed |
| WO-2011120655-A1 | SCALE INHIBITOR | CLARIANT INTERNATIONAL LTD (CH) | 2011-10-06 | — | — | WO | claimed |
| US-20110207044-A1 | TUNABLE GLOSS TONERS | XEROX CORPORATION (US) | 2011-08-25 | — | — | US | claimed |
| WO-2011031127-A1 | METHOD FOR ISOLATING DNA | UNIVERSITI PUTRA MALAYSIA (MY) | 2011-03-17 | — | — | WO | claimed |
| US-20110033399-A1 | THERAPEUTIC VITAMIN D SUN-PROTECTING FORMULATIONS AND METHODS FOR THEIR USE | AVIDAS PHARMACEUTICALS LLC | 2011-02-10 | — | — | US | claimed |
| WO-2011017380-A1 | THERAPEUTIC VITAMIN D SUN-PROTECTING FORMULATIONS AND METHODS FOR THEIR USE | AVIDAS PHARMACEUTICALS LLC (US) | 2011-02-10 | — | — | WO | claimed |
| WO-2010044094-A2 | A TOPICAL COMPOSITION FOR THE TREATMENT OF ERECTILE DYSFUNCTION | AGARWAL KRISHNA RADHARAMAN (IN) | 2010-04-22 | — | — | WO | claimed |
| WO-2009038607-A1 | METHOD FOR SELECTIVELEY STAINING MICROORGANISMS | UNIVERSITY OF WYOMING (US) | 2009-03-26 | — | — | WO | claimed |
| US-20090011458-A1 | Method for selectively staining microorganisms | UNIVERSITY OF WYOMING | 2009-01-08 | — | — | US | claimed |
| EP-1501537-A4 | MANNOSE BINDING LECTIN AND USES THEREOF | QUEENSLAND INST MED RES (AU) | 2008-01-16 | — | — | EP | claimed |
| EP-1501537-A1 | MANNOSE BINDING LECTIN AND USES THEREOF | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2005-02-02 | — | — | EP | claimed |
| WO-2003090774-A1 | MANNOSE BINDING LECTIN AND USES THEREOF | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2003-11-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185803-A1 | PROCESS FOR THE PREPARATION OF MACROCYCLIC POLYAZACARBOXYLATE LIGANDS AND CHELATES | SSTR4, SSTR5, MVD | ADRA2A 4269/4885TDP1 2543/4885EYA2 4566/4885 |
| US-20150259304-A1 | PROCESS FOR THE PREPARATION OF MACROCYCLIC POLYAZACARBOXYLATE LIGANDS AND CHELATES | SSTR4, SSTR5, MVD | ADRA2A 4269/4885TDP1 2543/4885EYA2 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.